- Home
- ACIC vs FULC Comparison
ACIC vs FULC Comparison
Compare ACIC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$7.93
Company Overview
Basic Information| Metric | ACIC | FULC |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.2M | 718.4M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACIC | FULC |
|---|---|---|
| Price | $11.57 | $7.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 321.7K | ★ 1.0M |
| Earning Date | 05-21-2026 | 05-19-2026 |
| Dividend Yield | ★ 6.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $296,657,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $7.23 | ★ N/A |
| Revenue Growth | ★ 3.53 | N/A |
| 52 Week Low | $9.97 | $2.32 |
| 52 Week High | $13.06 | $15.74 |
Technical Indicators
Market Signals| Indicator | ACIC | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 56.26 | 34.80 |
| Support Level | $11.53 | $6.33 |
| Resistance Level | $11.93 | $8.50 |
| Average True Range (ATR) | 0.44 | 0.80 |
| MACD | 0.07 | -0.17 |
| Stochastic Oscillator | 87.94 | 9.31 |
Price Performance
Historical Comparison ACIC
FULC
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.